Vivelle Dot 25 mikrog./24 timer depotplastre デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

vivelle dot 25 mikrog./24 timer depotplastre

sandoz a/s - estradiolhemihydrat - depotplastre - 25 mikrog./24 timer

Vivelle Dot 37,5 mikrog/24 timer depotplastre デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

vivelle dot 37,5 mikrog/24 timer depotplastre

sandoz a/s - estradiolhemihydrat - depotplastre - 37,5 mikrog/24 timer

Vivelle Dot 50 mikrog./24 timer depotplastre デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

vivelle dot 50 mikrog./24 timer depotplastre

sandoz a/s - estradiolhemihydrat - depotplastre - 50 mikrog./24 timer

Vivelle Dot 75 mikrog./24 timer depotplastre デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

vivelle dot 75 mikrog./24 timer depotplastre

sandoz a/s - estradiolhemihydrat - depotplastre - 75 mikrog./24 timer

Zonisamid "Glenmark" 100 mg kapsler, hårde デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

zonisamid "glenmark" 100 mg kapsler, hårde

glenmark arzneimittel gmbh - zonisamid - kapsler, hårde - 100 mg

Zonisamid "Glenmark" 50 mg kapsler, hårde デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

zonisamid "glenmark" 50 mg kapsler, hårde

glenmark arzneimittel gmbh - zonisamid - kapsler, hårde - 50 mg

Ztalmy 欧州連合 - デンマーク語 - EMA (European Medicines Agency)

ztalmy

marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - andre antiepileptika - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.

Lyxumia 欧州連合 - デンマーク語 - EMA (European Medicines Agency)

lyxumia

sanofi winthrop industrie - lixisenatid - diabetes mellitus, type 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Budesonid "Arrow" 0,125 mg/ml inhalationsvæske til nebulisator, suspension デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

budesonid "arrow" 0,125 mg/ml inhalationsvæske til nebulisator, suspension

teva b.v. - budesonid - inhalationsvæske til nebulisator, suspension - 0,125 mg/ml

Budesonid "Arrow" 0,25 mg/ml inhalationsvæske til nebulisator, suspension デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

budesonid "arrow" 0,25 mg/ml inhalationsvæske til nebulisator, suspension

teva b.v. - budesonid - inhalationsvæske til nebulisator, suspension - 0,25 mg/ml